Author:
Zhou Jun,Sun Yongkun,Zhang Wen,Yuan Jiajia,Peng Zhi,Wang Wei,Gong Jifang,Yang Lin,Cao Yanshuo,Zhao Hong,Chen Chao,Wang Weifeng,Shen Lin,Zhou Aiping
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference44 articles.
1. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‐up;Ann Oncol,2016
2. Presentation and outcomes with first‐line chemotherapy in advanced cholangiocarcinomas‐a relatively rare component of biliary tract cancers in India;South Asian J Cancer,2020
3. Real‐world efficacy and safety of nab‐paclitaxel plus gemcitabine‐cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis;Ther Adv Med Oncol,2021
4. Second‐line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC‐06): a phase 3, open‐label, randomised, controlled trial;Lancet Oncol,2021
5. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open‐label, randomised, phase 2b study;Lancet Oncol,2021
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献